MakroCare-Significantly Bringing down Data Costs per Patient

The healthcare analytics industry is forecasted to be worth $10.8 billion by 2017 and this growth can be attributed to the proliferation of Big Data and analytics in health care, which has brought the medical and information sciences together. However, there are several challenges faced by the industry and one of the major ones is constant rise of costs to bring new therapies to the market. Several areas and different functions contribute to this constant rise. Of all these, clinical development consume major pie. Data being the foundation for determining safety and efficacy of these new therapies, technology plays a key role in gathering data from different sources and integrating them for a holistic view. DDi (technology subsidiary of MakroCare) focuses on this specific area to facilitate data capture and move it in real time with advanced analytics for analysis.

“Breaking away from conventional thinking process, we have developed innovative solutions that facilitate Real-time decision making, Risk Based monitoring, Oversight/Governance, Central Statistical Monitoring, and key analytics all accomplished with a single integrated platform,” says Mahesh Malneedi, President and Co-Founder of MakroCare. The company leverages clients’ assets instead of starting solutions from scratch, to ensure faster implementation of RBM (Risk Based Monitoring) and Oversight projects as most of the pieces are pre-built. This enables functional teams to show the results faster in their projects and programs as compared to most IT projects wherein quantifying ROI takes long time. Sponsors can achieve high quality clinical informatics and intelligence pertaining to clinical operations, safety, data quality and regulatory compliance.

DDi focuses on this specific area to facilitate data capture and move it in real time with advanced analytics for analysis.

Considering the strong demand for achieving high quality data, real-time analytics, better control and faster decision making, DDi has developed an innovative clinical intelligence solution called 'ClinMetanoia'. The solution reduces the implementation time to larger extent by offering a basic set of pre-configured data models, metadata library covering most of the widely used data points and pre-configured analytics/ reports. It offers flexibility for soft integration (plug-in & play) with multiple data sources and also has in-built adapters to integrate with key e-clinical systems.

ClinMetanoia leverages DDi’s proprietary BIG Analytics Solution (BAS™) for better and proven algorithms/central statistical monitoring methods to drive down implementation time. Reports are presented in crisp and clear manner with an option of advanced visualization and real time alerts, resulting in faster data insights to stake holders so that key decisions can be made on time. “Our risk based approach is in line with the guidance from FDA, EMA and other health authorities. It starts with correct assessment of study-specific risks and their sources”, adds Mahesh.
DDi has given emphasis to People (consulting & advisory support), Process and Technology (ClinMetanoia & TULA) to help companies attain RBM goals. The company is focusing on development area currently and is looking to expand the reach of its products to other territories, with an aim to become a global leader in clinical informatics and analytics in next three years.